Neurofibromatoses
A group of disorders characterized by an autosomal dominant pattern of inheritance with high rates of spontaneous mutation and multiple neurofibromas or neurilemmomas. NEUROFIBROMATOSIS 1 (generalized neurofibromatosis) accounts for approximately 95% of cases, although multiple additional subtypes (e.g., NEUROFIBROMATOSIS 2, neurofibromatosis 3, etc.) have been described. (From Neurochirurgie 1998 Nov;44(4):267-72)
Subtype terms (2)
More specific conditions that are subtypes of Neurofibromatoses in the MeSH hierarchy.
- Neurofibromatosis 1
55 drugs (44 approved, 11 experimental)
- Neurofibromatosis 2
19 drugs (12 approved, 7 experimental)
Drugs by status
Approved for this indication (1)
Phase 4 trials (6)
Phase 3 trials (1)
Phase 2 trials (5)
Phase 1 trials (7)
Other trials (1)
Organizations
Organization Involved with Phase 4 Indications (4)
Organization Involved with Phase 3 Indications (5)
Organization Involved with Phase 2 Indications (61)
- Takeda
- AstraZeneca
- Genentech
- Pfizer
- Array BioPharma
- Bayer
- Betta Pharmaceuticals Co.,Ltd.
- GlaxoSmithKline
- PTC Therapeutics
- Simcere Pharmaceutical Co., Ltd
- Fundação Educacional Serra dos Órgãos
- National Institutes of Health (NIH)
- United States Army
- Region Skane
- Beijing Tiantan Hospital
- University of Pennsylvania
- University of Arizona
- University of Pittsburgh
- Burzynski Research Institute
- University of London
- Cornell University
- Harvard University
- Indiana University
- Johns Hopkins University
- Lund University
- McGill University
- Michigan State University
- New York University
- Northwestern University
- Pediatric Brain Tumor Consortium
- +31 more
Organization Involved with Phase 1 Indications (8)
Organization Involved with Other Experimental Indications (1)